Free Trial
OTCMKTS:MRMD

MariMed (MRMD) Stock Price, News & Analysis

MariMed logo
$0.11 -0.02 (-15.38%)
As of 08/15/2025 03:58 PM Eastern

About MariMed Stock (OTCMKTS:MRMD)

Key Stats

Today's Range
$0.11
$0.14
50-Day Range
$0.07
$0.13
52-Week Range
$0.07
$0.26
Volume
2.79 million shs
Average Volume
1.05 million shs
Market Capitalization
$42.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

MariMed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

MRMD MarketRank™: 

MariMed scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Percentage of Shares Shorted

    0.01% of the float of MariMed has been sold short.
  • Short Interest Ratio / Days to Cover

    MariMed has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MariMed has recently decreased by 48.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    MariMed does not currently pay a dividend.

  • Dividend Growth

    MariMed does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the float of MariMed has been sold short.
  • Short Interest Ratio / Days to Cover

    MariMed has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MariMed has recently decreased by 48.98%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    MariMed has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for MariMed this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added MariMed to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MariMed insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.99% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.18% of the stock of MariMed is held by institutions.

  • Read more about MariMed's insider trading history.
Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

MRMD Stock News Headlines

Noble Financial Has Bullish Outlook for MariMed Q3 Earnings
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
MariMed Inc. (MRMD) Q2 2025 Earnings Call Transcript
MariMed (MRMD) Q2 EPS Jumps to Positive
MariMed Reports Second Quarter 2025 Earnings
See More Headlines

MRMD Stock Analysis - Frequently Asked Questions

MariMed's stock was trading at $0.1158 on January 1st, 2025. Since then, MRMD shares have decreased by 5.0% and is now trading at $0.11.

MariMed Inc. (OTCMKTS:MRMD) announced its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The company had revenue of $37.96 million for the quarter, compared to the consensus estimate of $38.33 million. MariMed had a negative net margin of 10.14% and a negative trailing twelve-month return on equity of 10.52%.
Read the conference call transcript
.

Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MariMed investors own include Canopy Growth (CGC), Innovative Industrial Properties (IIPR), NVIDIA (NVDA), Curaleaf (CURLF), Aurora Cannabis (ACB), Meta Platforms (META) and Tilray Brands (TLRY).

Company Calendar

Last Earnings
5/07/2025
Today
8/17/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:MRMD
Previous Symbol
OTC:MRMD
CIK
1522767
Fax
N/A
Employees
260
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.16 million
Net Margins
-10.14%
Pretax Margin
-4.30%
Return on Equity
-10.52%
Return on Assets
-3.10%

Debt

Debt-to-Equity Ratio
1.25
Current Ratio
1.12
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$157.96 million
Price / Sales
0.27
Cash Flow
$0.02 per share
Price / Cash Flow
5.10
Book Value
$0.16 per share
Price / Book
0.69

Miscellaneous

Outstanding Shares
390,430,000
Free Float
316,291,000
Market Cap
$42.95 million
Optionable
Not Optionable
Beta
3.02
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (OTCMKTS:MRMD) was last updated on 8/17/2025 by MarketBeat.com Staff
From Our Partners